Search
Oleic Acid
go.drugbank.com/drugs/DB04224ApprovedInvestigationalVet approved(Stedman, 26th ed) … An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent.
Mixtures: Huile D'onagre Vitamin E, NEUROGAIN PB VEGICAP CAPSULE 500MGPalonosetron
go.drugbank.com/drugs/DB00377ApprovedInvestigationalPalonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). … It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of
Mixtures: AKYNZEO CAPSULES 300MG/0.5MG, Akynzeo (netupitant/palonosetron) 300mg/0.5mg Hard CapsulesSodium acetate
go.drugbank.com/drugs/DB09395ApprovedInvestigationalSodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. … It can be used also in metabolic acidosis and for urine alkalinization.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLGamolenic acid
go.drugbank.com/drugs/DB13854ApprovedWithdrawnGamolenic acid may be found in over-the-counter dietary supplements. Gamolenic acid is also found in some fungal sources and also present naturally in the form of triglycerides [F27]. … It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6; 6,9,12-octadecatrienoic acid; and cis-6, cis-9, cis-12- octadecatrienoic acid [F27].
Mixtures: Evening Primrose Oil Cap 500mg W Vit E, PRIM E CAPSULESynonyms: 18:3 (n-6)Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigationala range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. … Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms.
Products: SABRIL 500MG TABLETThyroid, porcine
go.drugbank.com/drugs/DB09100ApprovedInvestigational[A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. … [A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831]
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.
Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideIsatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalIsatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigationalMantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen.